This page shows the latest CytomX news and features for those working in and with pharma, biotech and healthcare.
In an unusual development, CytomX also gets a stake in an unnamed T-cell engaging bispecific developed at Amgen. ... Shares in US clinical stage biopharmaceutical company CytomX leaped more than a third on the latest deal.
MD Anderson Cancer Centre in the US, as well as earlier collaborations with InCyte and CytoMx.
CytomX has developed an ADC platform called Probody that it says can create ADCs that are safer and more effective than current technologies. ... The mask is designed to be removed in the presence of an enzyme that is found only in diseased cells, says
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
BMS has expanded its 2014 agreement with CytomX Therapeutics to access up to eight further targets in oncology and other fields, using CytomX’s Probody platform. ... 650. CytomX Therapeutics. BMS. Strategic collaboration. Probody platform to enhance
CytomX leads. Argenx undertakes R&D until IND, AbbVie thereafter it option exercised. ... Zymeworks, like CytomX, have multiple Big Pharma partners including Merck &Co and Lilly.
CytomX / BMS. Development and commercialisation licence. Selective monoclonal antibodies (“Probodies”) for up to 4 oncology targets.
BMS also entered into a platform deal with CytomX for so-called “Probodies,” monoclonal antibodies that are selectively activated within the cancer microenvironment.
818. CytomX / Pfizer. Collaboration and exclusive licence to selected PDCs.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Former VP of Eli Lilly and AstraZeneca joins the company. CytomX Therapeutics has appointed Dr Rachel Humphrey as chief medical officer. ... She said: “Since joining the CytomX board of directors in March, I have been able to see at first-hand the
CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... His new colleague Ray joined CytomX in 2011 and was instrumental in brokering the agreement with Pfizer.
More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...